Bhamidipati Castigliano M, Coselli Joseph S, LeMaire Scott A
Department of Surgery, State University of New York Upstate Medical University, Syracuse, New York, USA.
J Extra Corpor Technol. 2012 Mar;44(1):P6-12.
BioGlue surgical adhesive was developed as an adjunct for achieving hemostasis during cardiovascular surgery, and it was approved for use in the United States by the Food and Drug Administration in 2001. When applied to cardiovascular tissues, the glutaraldehyde and bovine serum albumin that comprise BioGlue produce strong crosslinking that bonds tissues and seals defects. These features have made BioGlue particularly well suited for preventing bleeding from fragile cardiovascular anastomoses such as those inherent in the repair of acute aortic dissection. Over the 10-year period since its approval, several studies and clinical reports have illuminated the relative risks and benefits of using BioGlue during cardiovascular operations. Understanding these merits and limitations of BioGlue is essential to ensuring its safe and effective use.
生物胶手术粘合剂是作为心血管手术中实现止血的辅助手段而开发的，2001年它在美国获得食品药品监督管理局的使用批准。当应用于心血管组织时，构成生物胶的戊二醛和牛血清白蛋白会产生强大的交联作用，从而使组织黏合在一起并封闭缺损处。这些特性使生物胶特别适合预防脆弱的心血管吻合口出血，比如急性主动脉夹层修复中固有的吻合口出血。自获批以来的10年里，多项研究和临床报告揭示了在心血管手术中使用生物胶的相对风险和益处。了解生物胶的这些优点和局限性对于确保其安全有效使用至关重要。
